{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "ASMB", "name": "Assembly Biosciences, Inc.", "url": "https://frontierpicks.com/dossiers/ASMB/", "json_url": "https://frontierpicks.com/dossiers/ASMB.json", "status": "WATCHLIST", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Assembly Biosciences confirmed its Gilead profit-share option on 2026-09-08, but its momentum thesis failed at the September 11 close below $30. The remaining development case requires GS-1179 to enter Phase 2 by year-end 2026; a disclosed delay into 2027 would invalidate that timetable.", "invalidation_trigger": "A weekly close below $30 invalidates the published momentum thesis; this condition was met on 2026-09-11 at $29.80. Separately, a disclosed GS-1179 Phase 2 delay into 2027 would invalidate the year-end development timetable.", "catalyst_date": "2026-09-16", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "precision-biotech-therapeutics" ], "tags": [], "sources": [], "notes": [ "All revenue is Gilead collaboration revenue; there is no approved product and no commercial sales line.", "Guidance for the opt-in decision and both Phase 2 starts is stated as 'by year-end 2026' — a window, not a fixed date.", "Weighted average share count was 18.9M in Q2 2026 vs 7.7M in Q2 2025; a small count means wide event-driven gaps.", "The 'runway into 2029' statement explicitly includes a $75M Gilead extension fee that had not yet been received at 2026-06-30.", "Gilead controls the development and commercial timetable for GS-1179; Assembly's US participation is optional and cost-bearing." ], "body_markdown": "## Current Thesis\n\nAssembly Biosciences has confirmed its participation in Gilead’s herpes program, but the September 11 close broke the published momentum thesis; clinical execution now depends on the promised year-end Phase 2 start. Assembly exercised its option on 2026-09-08 to share 40% of United States development costs and profits. The decision anticipated in the September 5 research note has therefore occurred. [Assembly’s September 8 announcement](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv)\n\nAs an interpretation of price structure, the narrative is dead in its previously published momentum form — the 2026-09-11 weekly close of $29.80 breached the September 5 thesis-break condition of $30. That observation does not establish clinical failure. It establishes that the published price condition failed despite the anticipated corporate decision arriving.\n\n## Bull Case\n\n- **Participation economics are now established.** The 2026-09-08 announcement specifies the US cost-and-profit share and eligibility for up to $280 million in milestones plus royalties outside the United States. Those are contingent economics, not booked revenue. [September 8 release](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv)\n- **Management maintained its funding outlook.** On 2026-09-08, Assembly reiterated expected funding into 2029, including a $75 million Gilead payment due in the fourth quarter of 2026. Nonreceipt of that payment would contradict an explicit assumption supporting the outlook. [September 8 release](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv)\n- **The balance sheet precedes development spending.** Assembly’s 2026-08-13 results reported $320.4 million in cash, equivalents and marketable securities at 2026-06-30 after a $115 million gross financing during the quarter. These are measured resources; they do not establish eventual profitability. [Second-quarter results](https://investor.assemblybio.com/node/14616)\n\n## Bear Case\n\n- **The published structure has failed.** The adjusted market close was $29.80 on 2026-09-11, below the previously published $30 weekly threshold. Retaining that threshold records the failure without moving the condition after the event.\n- **Revenue does not measure product demand.** The 2026-08-13 results reported $13.374 million of second-quarter collaboration revenue and a $3.9 million net loss. The collaboration revenue line cannot establish commercial uptake of an investigational medicine. [Second-quarter results](https://investor.assemblybio.com/node/14616)\n- **Financing expanded the equity denominator.** The 2026-08-13 results reported weighted average shares of 18.9 million for the second quarter of 2026 versus 7.7 million a year earlier. The disclosed financing is evidence of dilution; it does not establish that another offering is imminent. [Second-quarter results](https://investor.assemblybio.com/node/14616)\n\n## Setup & Price Structure\n\nThe supplied adjusted market series records a 2026-09-11 close of $29.80, 22.6% below its $38.50 trailing annual high, while the three-month price change remained positive at 29.8%. The 14-period relative strength index (RSI) was 33.4. These observations establish weakened momentum, but the available observations are too few to establish a durable base or a reversal probability.\n\nThe September 8 Benzinga headlines concern the same option exercise; their clustering does not establish independent buying participation. No moving-average value, short-interest series, fund-flow series or current insider-transaction evidence is supplied. Crowding therefore remains unmeasured. The second-quarter financing is the dated share-supply evidence available here.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-12-31 — Clinical guidance deadline.** Beyond the next 30 days, the 2026-09-08 release expects GS-1179 to enter Phase 2 for recurrent genital herpes by year-end. This is a guidance deadline, not a scheduled announcement. A disclosed postponement into 2027 would invalidate the on-time development case. [September 8 release](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv)\n\n## Elapsed catalysts\n\n- **2026-09-16 — Management conference appearance.** Assembly’s 2026-09-10 announcement schedules a fireside chat at the H.C. Wainwright Global Investment Conference for 8:30 a.m. Eastern Time. The announcement promises a presentation, without specifying new clinical results; it cannot establish an upcoming data readout. [Company conference announcement](https://www.globenewswire.com/news-release/2026/09/10/3359979/16259/en/assembly-biosciences-to-present-at-the-h-c-wainwright-co-28th-annual-global-investment-conference.html) *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nThe loss of the published price threshold has already settled the earlier momentum case: a weekly close below $30 occurred on 2026-09-11 at $29.80. The completed option exercise cannot reverse that recorded outcome.\n\nA weekly close above $30 would contradict continued weakness beneath that reference level, but would not by itself establish a new base. Company confirmation that GS-1179 has entered Phase 2 by 2026-12-31 would satisfy the next development milestone; an explicit delay beyond that deadline would break the timely-execution case.\n\n## Correlation Notes\n\nThis remains a single-name setup in the 2026-09-13 coverage context; no active thematic cluster or paired return series is supplied. A measured correlation with biotechnology shares or Gilead cannot be stated. The documented connection is operational: Gilead retains development and commercialization responsibility under the 2026-09-08 announcement. [September 8 release](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv)", "first_seen": "2026-09-02", "last_analyzed": "2026-09-13T11:49:48+00:00", "last_synthesized": "2026-09-13", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }